You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in Denmark

Jul 2011

Price: $2,400

About this Report

About this Report

Delivery method: instant download
Report format: PDF doc_pdf.png (download a sample)
Market statistics: Excel workbook doc_excel_table.png (download a sample)

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in Denmark with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in Denmark, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in Denmark for free:

The Consumer Health in Denmark market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in Denmark?
  • What are the major brands in Denmark?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Sample Analysis

EXECUTIVE SUMMARY

Increasing health problems drive up OTC sales

Increasing health problems and safety concerns, and a downward price trend, contributed to a modest value growth of consumer health sales in 2010. The strong health and wellness trend continued to drive sales of consumer health products, however growth was slower than in 2009 and the review period. Current value growth decreased due to rising consumer concerns about side effects and potential risks of some products, such as calming and sleeping, NRT smoking cessation aids, herbal/traditional products and vitamins and dietary supplements. Price reductions of health care products also drove down current value growth. The increasing number of people who suffer from changes of environment and climate conditions, modern lifestyles and stress-related problems such as headaches, neck pain, stomach ache, eye allergy problems etc, drove up current value of eye care, cough, cold and allergy (hay fever) remedies, analgesics, digestive remedies, medicated skin care, sports nutrition and weight management.

Negative economic climate increases OTC products consumption

The prolonged negative economic climate and the rising unemployment rate caused increasing consumer stress-related health problems such as headaches, neck pain and stomach ache. This led to growth in analgesics and digestive remedies.

Safety concerns slow down value growth

There were more unfavourable views from the authorities and experts on the side effects and risks of taking herbal/traditional products and some vitamins and dietary supplements, and these views caused a decline in consumer demand. Sales of NRT smoking cessation aids declined due to increasing criticism of it being unhealthy and creating dependency.

Prices in a downward trend

Average unit price of consumer health products saw a downward trend due to the falling medicine prices at chemists/pharmacies and the widening distribution into grocery retailers and internet retailing, where prices are cheaper. In addition, price reductions in vitamins and dietary supplements and herbal/traditional products prevented the growth of average unit price. Cheaper generic products and parallel imports rapidly developed in the market, benefiting from encouragement by the Danish government.

Stagnant sales forecast

Demand is expected to increase for all consumer health products over the forecast period. However, value forecast is stagnant as downward price pressures are expected to offset growing volume sales.

Table of Contents

Table of Contents

Consumer Health in Denmark - Industry Overview

EXECUTIVE SUMMARY

Increasing health problems drive up OTC sales

Negative economic climate increases OTC products consumption

Safety concerns slow down value growth

Prices in a downward trend

Stagnant sales forecast

KEY TRENDS AND DEVELOPMENTS

Chemists/pharmacies continues to dominate consumer health

Safety concerns lead to slowdown in sales growth

Unit prices expected to decrease

Dynamic growth continues in internet retailing

Stress-related health problems increase consumption of OTC products

MARKET INDICATORS

  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2005-2010
  • Table 2 Life Expectancy at Birth 2005-2010

MARKET DATA

  • Table 3 Sales of Consumer Health by Category: Value 2005-2010
  • Table 4 Sales of Consumer Health by Category: % Value Growth 2005-2010
  • Table 5 Consumer Health Company Shares by Value 2006-2010
  • Table 6 Consumer Health Brand Shares by Value 2007-2010
  • Table 7 Penetration of Private Label by Category 2005-2010
  • Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2005-2010
  • Table 9 Sales of Co%nsumer Health by Category and Distribution Format: % Analysis 2010
  • Table 10 Forecast Sales of Consumer Health by Category: Value 2010-2015
  • Table 11 Forecast Sales of Consumer Health by Category: % Value Growth 2010-2015

APPENDIX

OTC Registration and Classification

Vitamins and dietary supplements registration and classification

Self-medication/self-care and preventive medicine

Switches

  • Summary 1 OTC Healthcare Switches 2008-2010

DEFINITIONS

Sources

  • Summary 2 Research Sources

Consumer Health in Denmark - Company Profiles

Actavis Nordic A/S in Consumer Health (Denmark)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 5 Actavis Nordic A/S: Competitive Position 2010

Axellus A/S in Consumer Health (Denmark)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 8 Axellus A/S: Competitive Position 2010

Ferrosan A/S in Consumer Health (Denmark)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 11 Ferrosan A/S: Competitive Position 2010

Nycomed Danmark A/S in Consumer Health (Denmark)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 14 Nycomed Danmark A/S: Competitive Position 2010

Orifarm A/S in Consumer Health (Denmark)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 17 Orifarm A/S: Competitive Position 2010

Adult Mouth Care in Denmark - Category Analysis

HEADLINES

TRENDS

  • Value share of adult mouth care continued its declining trend over the review period and in 2010, when it decreased by -2%. Danish consumers seek dentists’ advice when suffering mouth ulcers, canker sores and inflammation, rather than self medication. This resulted in lower consumer demand for adult mouth care products.

SWITCHES

COMPETITIVE LANDSCAPE

  • McNeil Denmark A/S led the market with 31% value share in 2010. The company benefited from the strength of its brand Hextril, which is an antiseptic mouthwash for disinfection and cleaning of the mouth and throat. Hextril comes in mouthwash format for disinfection and cleaning of the mouth and throat with two products: Hextril and Hextril Mint. The brand gradually gained value share over the review period and won consumer credibility. In 2010, it continued to gain by one percentage point.

PROSPECTS

  • The low consumer demand for adult mouth care products is unlikely to change in the forecast period and negative growth is therefore expected to continue throughout the forecast period with a -2% CAGR to reach DKr20 million.

CATEGORY DATA

  • Table 12 Sales of Adult Mouth Care: Value 2005-2010
  • Table 13 Sales of Adult Mouth Care: % Value Growth 2005-2010
  • Table 14 Adult Mouth Care Company Shares by Value 2006-2010
  • Table 15 Adult Mouth Care Brand Shares by Value 2007-2010
  • Table 16 Forecast Sales of Adult Mouth Care: Value 2010-2015
  • Table 17 Forecast Sales of Adult Mouth Care: % Value Growth 2010-2015

Analgesics in Denmark - Category Analysis

HEADLINES

TRENDS

  • Analgesics value increased by 2% to reach DKr525 million in 2010. The sales growth was mainly driven by Danish consumers' increasing stress-related health problems, such as headaches, neck pain and stomach ache, caused by the negative economic climate. Many of the consumers use analgesics when they feel stressed. According to the investigation by National Institute of Public Health, stress is a growing public health problem in Denmark, and 10%-12% of Danes have symptoms of severe stress every day. Many people perceive it as safe, easy and fast to cope with their stress with OTC medications. According to a new study by the National Institute of Public Health at Southern University and the Faculty of Pharmaceutical Sciences at the University, 25-44 year olds represent the population with the highest stress levels and the highest consumption of OTC drugs for pain treatment.

SWITCHES

COMPETITIVE LANDSCAPE

  • Analgesics is highly concentrated as the top five manufacturers controlled 96% of value sales in 2010. This is in large part due to limited distribution options as sales are largely restricted to chemists/pharmacies, which accounted for 98% of distribution in 2010. Holding a 40% value share, Nycomed Danmark A/S was the leading manufacturer. Its brand portfolio includes the well-known systemic analgesics Pamol and Kodimagnyl “DAK”. The other top five players were respectively GlaxoSmithKline Consumer HealthCare A/S, Actavis Nordic A/S, McNeil Denmark A/S and Novartis Healthcare A/S.

PROSPECTS

  • Demand for analgesics is likely to stagnate over the forecast period at a 1% CAGR. Danish consumers’ increasing stress-related health problems fuel the growing demand for OTC analgesics. Value growth was negatively affected by rising consumer concerns over the safety of self-medicating with analgesics due to information about the dangers of overdosing and analgesics dependency.

CATEGORY DATA

  • Table 18 Sales of Analgesics by Category: Value 2005-2010
  • Table 19 Sales of Analgesics by Category: % Value Growth 2005-2010
  • Table 20 Topical Analgesics/Anaesthetic by Format: % Value Breakdown 2005-2010
  • Table 21 Analgesics Company Shares by Value 2006-2010
  • Table 22 Analgesics Brand Shares by Value 2007-2010
  • Table 23 Forecast Sales of Analgesics by Category: Value 2010-2015
  • Table 24 Forecast Sales of Analgesics by Category: % Value Growth 2010-2015

Calming and Sleeping in Denmark - Category Analysis

HEADLINES

TRENDS

  • Value share of calming and sleeping continued declining and dropped by -5% in current value terms to reach DKr35 million in 2010. In the same year, liver physicians warned that there were increasing reported cases of serious liver damage due to herbal remedies and dietary supplements. This made consumer more reluctant to seek calming and sleeping products for self medication, as the majority of OTC calming and sleeping medicines are herbal/traditional products. In 2010, 40 natural resources were exposed that were potentially toxic to the liver including valerian, which is the most common herbal ingredient in the manufacture of calming and sleeping products.

SWITCHES

COMPETITIVE LANDSCAPE

  • Axellus A/S led the market with 23% value share in 2010. The company’s brand Drogen's Baldrian B+ is long-established and is made from valerian to treat anxiety and insomnia. It has strong brand credibility amongst Danish consumers. Valerian has been used in Denmark for more than 20 years, and Drogen's Baldrian B+ had the best brand reputation amongst local users, greatly attributed to word-of-mouth. Over the review period, value share of Drogen's Baldrian B+ increased and has a stable leading position.

PROSPECTS

  • The downward sales trend of calming and sleeping products is unlikely to reverse over the forecast period, therefore a negative sales growth is forecasted at -5% CAGR to reach DKr27 million.

CATEGORY DATA

  • Table 25 Sales of Calming and Sleeping: Value 2005-2010
  • Table 26 Sales of Calming and Sleeping: % Value Growth 2005-2010
  • Table 27 Calming and Sleeping Company Shares by Value 2006-2010
  • Table 28 Calming and Sleeping Brand Shares by Value 2007-2010
  • Table 29 Forecast Sales of Calming and Sleeping: Value 2010-2015
  • Table 30 Forecast Sales of Calming and Sleeping: % Value Growth 2010-2015

Cough, Cold and Allergy (Hay Fever) Remedies in Denmark - Category Analysis

HEADLINES

TRENDS

  • The number of people who suffered from coughs and colds increased rapidly because of the unusual cold and snowy winter in 2010. Marketing remained the key value growth driver for cough, cold and allergy (hay fever) remedies. Manufacturers invested especially in promoting medicated confectionery such as Halls, nasal sprays such as Otrivin and Zymelin and pharyngeal preparations such as Strepsils. Widely distributed to grocery retailers, including impulse channels such as convenience stores and forecourt retailers, these well-known brands all target convenience through key slogans such as use on the move and by offering instant relief from cough and cold symptoms.

SWITCHES

COMPETITIVE LANDSCAPE

  • The three leading players, Novartis Healthcare, Nycomed Danmark and Cadbury Stimorol Danmark, target mainly convenience-driven demand for instant relief from cough and cold symptoms. Novartis and Nycomed respectively offer the two leading nasal sprays brands Otrivin and Zymelin. Novartis also offer the leading pharyngeal preparations brand Strepsils, and Cadbury Stimorol Danmark offers the leading medicated confectionery range Halls. These brands are all heavily marketed and widely distributed to chemists/pharmacies, parapharmacies/drugstores and grocery retailers. Halls is not a medicine and is thus most widely distributed, whilst Otrivin and Zymelin are amongst the most broadly distributed medicines in Denmark, surpassed only by the NRT smoking cessation aid brands Nicorette and Nicotinell.

PROSPECTS

  • Low demand for cough, cold and allergy (hay fever) remedies is expected to have a slightly negative growth over the forecast period, as the changing environment and weather conditions are likely to cause increasing consumer health problems. In addition, marketing and convenience are expected to remain the key positive growth drivers in cough and cold remedies, as leading multinational manufacturers are likely to continue investing in brands such as Strepsils, Otrivin, Zymelin and Halls. In addition, basic demand for allergy remedies is also likely to continue growing, and this will help boost forecast sales in antihistamines/allergy remedies (systemic) and nasal sprays. The National Institute of Public Health estimates that by 2020 the number of Danes suffering from allergies will increase to 1.7 million, up by 70% from 2007.

CATEGORY DATA

  • Table 31 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
  • Table 32 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
  • Table 33 Sales of Decongestants by Category: Value 2005-2010
  • Table 34 Sales of Decongestants by Category: % Value Growth 2005-2010
  • Table 35 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2006-2010
  • Table 36 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2007-2010
  • Table 37 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2010-2015
  • Table 38 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2010-2015

Digestive Remedies in Denmark - Category Analysis

HEADLINES

TRENDS

  • Digestive remedies value increased by 1% as DKr351 million sales were recorded in 2010. This was mainly because Danish chemists/pharmacies were offering more generics and parallel imports to provide the cheapest medicines to consumers. Sales value in chemists/pharmacies remained at the same level as 2009 although consumers were given more medicines, as sales of digestive remedies were mainly through chemists/pharmacies.

SWITCHES

COMPETITIVE LANDSCAPE

  • McNeil Denmark is a subsidiary of Johnson & Johnson Inc. Holding a current value share of 16%, the company maintained the leading position in digestive remedies. Its key brands Imodium and Imodium Plus were the leaders in diarrhoeal remedies, with a 58% combined value share in 2010. Imodium and Imodium Plus were the most widely distributed digestive remedies in the Danish market. Widening distribution and TV advertisements for these two brands underpinned the steady sales growth of the company.

PROSPECTS

  • Digestive remedies sales are expected to record positive value growth over the forecast period. Basic demand is expected to continue expanding due to the rising numbers of people suffering from indigestion. Official sources such as the Ministry of Health and Prevention expect this trend to continue. In addition, manufacturers are expected to target this growing trend in demand through heavy investment in marketing, and through widening distribution further into grocery retailers.

CATEGORY DATA

  • Table 39 Sales of Digestive Remedies by Category: Value 2005-2010
  • Table 40 Sales of Digestive Remedies by Category: % Value Growth 2005-2010
  • Table 41 Digestive Remedies Company Shares by Value 2006-2010
  • Table 42 Digestive Remedies Brand Shares by Value 2007-2010
  • Table 43 Forecast Sales of Digestive Remedies by Category: Value 2010-2015
  • Table 44 Forecast Sales of Digestive Remedies by Category: % Value Growth 2010-2015

Ear Care in Denmark - Category Analysis

HEADLINES

TRENDS

  • Value share of ear care products continued to grow at a moderate rate of 2% to DKr14 million in 2010. Ear care in Denmark is insignificant as most of the ear treatment products are prescription medicines, and Danes do not usually deal with their ear infections and other problems through self medication. Over the review period, the small value share of ear care attracted only minimal investment in product development and marketing.

SWITCHES

COMPETITIVE LANDSCAPE

  • Orion Pharma A/S led ear care with a 70% value share in 2010. The company’s ear care brand Remo-Wax is on the Danish market since 1970. Benefiting from its long history in the market, Remo-Wax won the majority of users’ trust. Medic Team A/S was in second positions with a 26% value share with its brand Glycerol Øredråber.

PROSPECTS

  • Lack of product innovation and marketing investment is the key threat to sales growth of ear care products. Value share of ear care products are expected to slowly develop at a CAGR of less than 1% in 2010-2015. The forecast growth is lower than the 2% CAGR in the review period, due to the continuous downward price trend of medicine, which drives down value growth. Cheaper parallel imports and generics are increasingly offered at chemists/pharmacies and are expected to expand sales volume over the forecast period.

CATEGORY DATA

  • Table 45 Sales of Ear Care: Value 2005-2010
  • Table 46 Sales of Ear Care: % Value Growth 2005-2010
  • Table 47 Ear Care Company Shares by Value 2006-2010
  • Table 48 Ear Care Brand Shares by Value 2007-2010
  • Table 49 Forecast Sales of Ear Care: Value 2010-2015
  • Table 50 Forecast Sales of Ear Care: % Value Growth 2010-2015

Emergency Contraception in Denmark - Category Analysis

HEADLINES

TRENDS

  • Value share of emergency contraception grew by1% in current value terms to reach DKr11 million in 2010. Consumer demand was affected by the prolonged recession and became stagnant in 2009, when value share grew by 1% after reaching a peak in 2001. The slower sales development in 2010 was partly due to the prolonged negative economic climate, which resulted in less spending on evening events and social entertainment amongst the youth, and thus the lower demand for emergency contraception. It was also partly due to the growing mistrust of the effectiveness of emergency contraception, as a high proportion of users became pregnant even though they took emergency contraception pills. According to the latest report from the Danish Health Protection Agency, 17% of 15-24 year-old women who underwent an abortion took the emergency contraception pills but had a contraceptive failure.

COMPETITIVE LANDSCAPE

  • Nycomed Danmark A/S dominated the market with 84% value share in 2010. Despite the price competition amongst other manufacturers, such as Paranova Danmark and 2care4 who offered cheaper parallel imports of NorLevo, Nycomed NorLevo retained the highest price in the market. In 2010, Nycomed NorLevo gained two percentage points of value share from Orifarm NorLevo, as the licensing of Orifarm NorLevo expired at the end of 2009. The product therefore exited the market in 2010.

SWITCHES

PROSPECTS

  • The growing speed of sales value is expected to slow down over the forecast period with a 1% constant value CAGR in 2010-2015. Restricted sales to chemists/pharmacies and increasing consumer mistrust will be the key threats to sales growth. Price competition from parallel imports will also drive down unit prices and value growth.

CATEGORY DATA

  • Table 51 Sales of Emergency Contraception: Value 2005-2010
  • Table 52 Sales of Emergency Contraception: % Value Growth 2005-2010
  • Table 53 Emergency Contraception Company Shares by Value 2006-2010
  • Table 54 Emergency Contraception Brand Shares by Value 2007-2010
  • Table 55 Forecast Sales of Emergency Contraception: Value 2010-2015
  • Table 56 Forecast Sales of Emergency Contraception: % Value Growth 2010-2015

Eye Care in Denmark - Category Analysis

HEADLINES

TRENDS

  • Eye care sales continued to grow by 3% in 2010 due to growing allergy problems in the population and modern lifestyles which cause eye conditions, especially dry eye. People spend more time indoors, in front of the TV or computer screens, and use air conditioning and central heating.

SWITCHES

COMPETITIVE LANDSCAPE

  • Novartis Healthcare A/S led the market with a 32% value share in 2010. The company held a 39% value share in standard eye care, and its brands Viscotears and Oculac were the top two brands in standard eye care with 40% combined share. Both Viscotears and Oculac are symptomatic treatments of dry eye.

PROSPECTS

  • Sales of eye care are expected to reach DKr71 million by 2015 with a 1% constant value CAGR in 2010-2015. The forecast growth is slower than the 2% CAGR in the review period, due to the continuous downward medicine price trend, which drives down value growth. Cheaper parallel imports and generics are increasingly offered at chemists/pharmacies and are expected to expand sales volume over the forecast period. This is because the Danish Interior and Ministry of Health will continue to control OTC medicine price to reduce costs to the government and private users.

CATEGORY DATA

  • Table 57 Sales of Eye Care by Category: Value 2005-2010
  • Table 58 Sales of Eye Care by Category: % Value Growth 2005-2010
  • Table 59 Standard Eye Care by Type: % Value Breakdown 2007-2010
  • Table 60 Eye Care Company Shares by Value 2006-2010
  • Table 61 Eye Care Brand Shares by Value 2007-2010
  • Table 62 Forecast Sales of Eye Care by Category: Value 2010-2015
  • Table 63 Forecast Sales of Eye Care by Category: % Value Growth 2010-2015

Herbal/Traditional Products in Denmark - Category Analysis

HEADLINES

TRENDS

  • Value share of herbal/traditional products decreased by current value -1% to reach DKr462 million in 2010, as the unfavourable market conditions continued to drive down consumer demand. In 2010, there were more unfavourable medical opinions towards the side effects and potential risks of herbal/traditional products. For instance, liver physicians warned that there was an increasing number of reported cases of serious liver damage due to herbal remedies and dietary supplements. Cardiologists also warned that some herbal/traditional products can cause dangerous side effects and risks for patients who are already taking traditional medicines. In 2010, there were 40 potentially liver toxic herbal/traditional resources exposed to the public. Many of these herbal/traditional resources were widespread like St John's wort, mint and valerian. Such warnings affected herbal/traditional products unfavourably and made consumers more reluctant to seek herbal/traditional products for self medication.

COMPETITIVE LANDSCAPE

  • Herbal/traditional products continues to remain fragmented with 61% value share shared between small market players in 2010. Cadbury Stimorol Danmark and Axellus A/S led with very close value share, at 13% and 12% respectively in 2010. All sales of Cadbury Stimorol Danmark are in herbal/traditional cough, cold and allergy (hay fever) remedies with the leading medicated confectionery range Halls, which had a 28% value share in 2010.

PROSPECTS

  • Sales of herbal/traditional products are expected to decline over the forecast period by a -1% constant value CAGR to DKr436 million in 2015. The market environment for herbal/traditional products is expected to remain tough over the forecast period. The medical establishment in Denmark is unlikely to change attitudes since it is heavily involved with the pharmaceuticals industry, and will thus continue to favour non-herbal/traditional OTC and prescription medicines over herbal/traditional products.

CATEGORY DATA

  • Table 64 Sales of Herbal/Traditional Products: Value 2005-2010
  • Table 65 Sales of Herbal/Traditional Products: % Value Growth 2005-2010
  • Table 66 Herbal/Traditional Products Company Shares 2006-2010
  • Table 67 Herbal/Traditional Products Brand Shares 2007-2010
  • Table 68 Forecast Sales of Herbal/Traditional Products: Value 2010-2015
  • Table 69 Forecast Sales of Herbal/Traditional Products: % Value Growth 2010-2015

Medicated Skin Care in Denmark - Category Analysis

HEADLINES

TRENDS

  • Sales of medicated skin care continued to grow by 3% in 2010. The sales growth was an improvement on the review period CAGR of 2%, mainly driven by increasing consumer demand caused by the warm and humid late spring and summer seasons. Topical antifungals had the most dynamic value growth in 2010 at 10%. Antipruritics and topical allergy remedies/antihistamines also recorded significant current value growth of 8% and 9% respectively. Meanwhile, medicated shampoos and hair loss treatment continued a downward trend with -6% and -5% respectively.

SWITCHES

PROSPECTS

  • Fluctuations in demand are expected in the forecast period, with a constant value growth of less than 1% in 2010-2015. The level of consumer demand depends on many factors, such as seasonal reasons, product innovation, brand marketing, etc. For instance, demand for topical antifungals is occasionally seasonal in warm and humid late spring and summer seasons, whilst product innovation and marketing are expected to underpin forecast value growth in acne treatments, which has strong international brand names such as Clearasil and Basiron.

CATEGORY DATA

  • Table 70 Sales of Medicated Skin Care by Category: Value 2005-2010
  • Table 71 Sales of Medicated Skin Care by Category: % Value Growth 2005-2010
  • Table 72 Acne Treatments by Format: % Value Breakdown 2005-2010
  • Table 73 Medicated Skin Care Company Shares by Value 2006-2010
  • Table 74 Medicated Skin Care Brand Shares by Value 2007-2010
  • Table 75 Acne Treatments Brand Shares by Value 2007-2010
  • Table 76 Hair Loss Treatments Brand Shares by Value 2007-2010
  • Table 77 Forecast Sales of Medicated Skin Care by Category: Value 2010-2015
  • Table 78 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2010-2015

NRT Smoking Cessation Aids in Denmark - Category Analysis

HEADLINES

TRENDS

  • After strong growth in the review period, value share of NRT smoking cessation aids declined by -9% in 2009 and by -3% in 2010. The sales decline was due in part to rising consumer concerns about dependency on NRT smoking cessation aids, and to product price reduction, which drove down value growth. In 2010, retail prices of NRT smoking cessation aids were reduced 1%. NRT smoking cessation aids faced increasing criticism for being unhealthy and creating dependency amongst some of its users. The authorities frequently warned about increasing nicotine addiction and the unknown long-term effects, and started to provide free help to quit smoking and to discontinue the use of nicotine replacement therapy products, which resulted in declining consumption.

SWITCHES

COMPETITIVE LANDSCAPE

  • McNeil Denmark A/S and Novartis Healthcare A/S had a monopoly on NRT smoking cessation aids. Their two brands, Nicorette by McNeil Denmark A/S and Nicotinell by Novartis Healthcare A/S, dominated with respective shares of 52% and 46% in 2010. Nicotinell is only available in lozenge, patch and gum formats. Nicorette offer a broader product portfolio, including inhalators and nasal sprays. Both companies are expanding distribution into grocery retailers and internet retailers. The products are also widely available in chemists/pharmacies and parapharmacies/drugstores.

PROSPECTS

  • Sales of NRT smoking cessation aids are expected to increase slightly over the forecast period at a 1% CAGR during the 2010-2015 period. The 2010-2015 CAGR is identical to the -2% CAGR during the 2005-2010 period, when sales of NRT smoking cessation aids had exploded mainly because of the growing consumer demand and the widening distributing channels. Rising consumer concerns about dependency on NRT smoking cessation aids is the key threat to sales growth, as consumers are expected to switch to non-medical aids or will power to quit smoking.

CATEGORY INDICATORS

  • Table 79 Number of Smokers by Gender 2005-2010

CATEGORY DATA

  • Table 80 Sales of NRT Smoking Cessation Aids by Category: Value 2005-2010
  • Table 81 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2005-2010
  • Table 82 NRT Gum Flavours: % Value Breakdown 2006-2010
  • Table 83 NRT Smoking Cessation Aids Company Shares by Value 2006-2010
  • Table 84 NRT Smoking Cessation Aids Brand Shares by Value 2007-2010
  • Table 85 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2010-2015
  • Table 86 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2010-2015

Sports Nutrition in Denmark - Category Analysis

HEADLINES

TRENDS

  • Despite the prolonged negative economic climate, sports nutrition continued to grow by 3% in 2010, driven by the continuing health and fitness trend. Increasing consumer interest in fitness and growing gym membership continued to boost demand. The growing Danish interest in fitness is driven by two key trends, namely health and wellness, and a growing public obsession with beauty. Similar to tendencies in most other developed countries, the two trends have their respective roots in the long-term obesity problem and the media's idealisation of beauty. The need to counter sedentary lifestyles through fitness and sport is increasingly taking a central role in the Danish health debate within the mainstream media

COMPETITIVE LANDSCAPE

  • The competitive environment is dominated by three players: Maxim Danmark A/S, Nutramino ApS Bodylab and Nutrition Aps held respective value share of 36%, 16% and 16% in 2010. Maxim Danmark and Nutramino both have a strong presence in sales from fitness centres. Their main source of sales growth is, however, through widening distribution into grocery retailers. Bodylab Nutrition sales are entirely through internet retailing; the company operates its own website shop and offers competitive prices through bypassing retailer markups.

PROSPECTS

  • Sales of sports nutrition are expected to have a constant value CAGR of less than 1% to reach DKr120 million in 2015. Sports nutrition sales will remain limited to a small consumer group, as Danes are traditionally highly sceptical of fortified foods, especially if these are for performance enhancement of any kind.

CATEGORY DATA

  • Table 87 Sales of Sports Nutrition: Value 2005-2010
  • Table 88 Sales of Sports Nutrition: % Value Growth 2005-2010
  • Table 89 Sports Nutrition By Format: % Value Breakdown 2007-2010
  • Table 90 Sports Nutrition Company Shares 2006-2010
  • Table 91 Sports Nutrition Brand Shares 2007-2010
  • Table 92 Forecast Sales of Sports Nutrition: Value 2010-2015
  • Table 93 Forecast Sales of Sports Nutrition: % Value Growth 2010-2015
  • Table 94 Sports Nutrition: Category Rankings

Vitamins and Dietary Supplements in Denmark - Category Analysis

HEADLINES

TRENDS

  • Value share of vitamins and dietary supplements saw a decrease of -1% in current value terms in 2010. This was due to the prolonged recession and rising unemployment rate which resulted in declining consumer demand, as financially concerned consumers cut back spending on non-essentials, which include vitamins and dietary supplements. Secondly, there were more unfavourable views from the authorities and experts on the risks of some vitamins and dietary supplements. Thirdly, manufacturers’ price discounting of vitamins and dietary supplements partially offset sales value growth.

Vitamins

Dietary Supplements

COMPETITIVE LANDSCAPE

  • Axellus led vitamins and dietary supplements with a 25% value share in 2010. The company furthermore manufactures most private label products in the Danish market, including the Matas private label range. The company has strong umbrella brands such as Livol and Futura and has a particularly strong standing in grocery retailers. Its nearest competitor, Mezina, leads innovation in combination dietary supplements marketed towards specific health benefits such as mental alertness, relief of stress and a stronger immune system. The company is furthermore the largest supplier to the nationwide Matas drugstore chain.

PROSPECTS

  • Increasingly rising consumer concerns about side effects is expected to affect demand. Value share of vitamins and dietary supplements is thus expected to continue a slow development with -1% CAGR in 2010-2015.

CATEGORY DATA

  • Table 95 Sales of Vitamins and Dietary Supplements by Category: Value 2005-2010
  • Table 96 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2005-2010
  • Table 97 Dietary Supplements by Positioning 2005-2010
  • Table 98 Vitamins and Dietary Supplements Company Shares by Value 2006-2010
  • Table 99 Vitamins and Dietary Supplements Brand Shares by Value 2007-2010
  • Table 100 Vitamins Brand Shares by Value 2007-2010
  • Table 101 Dietary Supplements Brand Shares by Value 2007-2010
  • Table 102 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2010-2015
  • Table 103 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2010-2015
  • Summary 18 Dietary Supplements Brand Ranking by Positioning

Weight Management in Denmark - Category Analysis

HEADLINES

TRENDS

  • Value share growth was driven by the health and wellness trend, including growing consumer concerns about being overweight and obesity, and interest in beauty. The severe problem of obesity and being overweight continued to rise in Denmark. According to a study by Rockwool Foundation Research Unit, 12-13% of the Danish population age 25-44 were obese in 2009, an increase from 11% in 2005 and only 3-5% in 1987. This trend gave many opportunities to manufacturers of weight management products.

COMPETITIVE LANDSCAPE

  • Nupo A/S led with a 32% value share in 2010. The company established a high level of consumer trust, loyalty and brand recognition over the review period. Nupo spearheads innovation and marketing efforts on its three product groups: diet products under Nupo Classic, known as Very Low Calorie Diet (VLCD); Meal replacement under Nupo Control, know as Low Calorie Diet (LCD); and Snack bar. Product formats include shakes, soups, bars, drinks and powders.

PROSPECTS

  • Weight management is expected to grow at a constant value 2% CAGR in 2010-2015, as health and wellness is expected to underpin growing demand for weight management products over the forecast period. Nupo is likely to target this trend and increase sales through product innovation and brand development. Thus, meal replacement slimming is expected to increase value growth in weight management over the forecast period.

CATEGORY DATA

  • Table 104 Sales of Weight Management: Value 2005-2010
  • Table 105 Sales of Weight Management: % Value Growth 2005-2010
  • Table 106 Weight Management Company Shares 2006-2010
  • Table 107 Weight Management Brand Shares 2007-2010
  • Table 108 Forecast Sales of Weight Management: Value 2010-2015
  • Table 109 Forecast Sales of Weight Management: % Value Growth 2010-2015

Wound Care in Denmark - Category Analysis

HEADLINES

TRENDS

  • Value share of wound care declined by -1% in current value terms to reach DKr58 million in 2010. This was because consumers reduced their spending on non-essentials, which include wound care products, in the prolonged negative economic climate. The impact of the recession since mid-2008 resulted in slow sales development in wound treatments over the review period, and further affected sales growth in 2010. When the economic situation became worse, consumers reduced buying wound care products and used existing reserve products, or sought emergency medical treatment which has no charge.

COMPETITIVE LANDSCAPE

  • Salvequick by Cederroth A/S led wound care with more than 35% value share and was the fastest-growing wound treatment brand in 2010. The company also grew the fastest as its value share grew by one percentage point compared to 2009. Through its broad and innovative product portfolio, the brand managed to differentiate itself from the rapidly emerging private label ranges which increasingly offer high quality standard plasters.

SWITCHES

PROSPECTS

  • Value share is expected to increase over the forecast period with a constant value CAGR of 1% to reach DKr60 million by 2015. The slow recovery of the economy is expected to be the key threat to market growth of wound care. Although wound care is likely to see continued product innovation and value growth in the Salvequick range, other leading brands like Hansaplast are expected to lose further value share to private label, which will thus undermine forecast growth in unit prices and sales.

CATEGORY DATA

  • Table 110 Sales of Wound Care by Category: Value 2005-2010
  • Table 111 Sales of Wound Care by Category: % Value Growth 2005-2010
  • Table 112 Wound Care Company Shares by Value 2006-2010
  • Table 113 Wound Care Brand Shares by Value 2007-2010
  • Table 114 Forecast Sales of Wound Care by Category: Value 2010-2015
  • Table 115 Forecast Sales of Wound Care by Category: % Value Growth 2010-2015

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Child-Specific Analgesics
            • Child-Specific Acetaminophen
            • Child-Specific Aspirin
            • Child-Specific Combination Products - Analgesics
            • Child-Specific Diclofenac
            • Child-Specific Dipyrone
            • Child-Specific Ibuprofen
            • Child-Specific Ketoprofen
            • Child-Specific Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Child-Specific Cough, Cold and Allergy Remedies
          • Child-Specific Allergy Remedies
          • Child-Specific Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Child-Specific Digestive Remedies
          • Child-Specific Diarrhoeal Remedies
          • Child-Specific Indigestion and Heartburn Remedies
          • Child-Specific Laxatives
          • Child-Specific Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Acne Treatments
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Child-Specific Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
    • Vitamins and Dietary Supplements
      • Child-Specific Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
            • Chlorella
            • Cranberry
            • Ginger
            • Isoflavones
            • Other Other Herbal/Traditional Dietary Supplements
        • Non-Herbal Dietary Supplements
          • Calcium Supplements
          • Co-Enzyme Q10
          • Combination Non-Herbal Dietary Supplements
          • Eye Health Supplements
          • Fish Oils
            • Cod Liver Oil
            • Other Fish Oils
          • Glucosamine
          • Mineral Supplements
          • Omega-3-6-9 (Fish and Non-Fish)
          • Probiotic Supplements
          • Protein Powder
          • Royal Jelly
          • Sam-E
          • Other Non-Herbal Dietary Supplements
            • Chromium
            • Propolis
      • Tonics and Bottled Nutritive Drinks
      • Vitamins
        • Multivitamins
        • Single Vitamins
          • Vitamin A
          • Vitamin B
          • Vitamin C
          • Vitamin D
          • Vitamin E
          • Other Single Vitamins
    • Weight Management
      • Meal Replacement Slimming
      • OTC Obesity
      • Slimming Teas
      • Weight Loss Supplements
      • Other Slimming Products
    • Herbal/Traditional Products
      • Herbal/Traditional Analgesics
      • Herbal/Traditional Calming and Sleeping Products
      • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
      • Herbal/Traditional Digestive Remedies
      • Herbal/Traditional Medicated Skin Care
      • Herbal/Traditional Medicinal Teas
      • Herbal/Traditional Smoking Cessation Aids
      • Herbal/Traditional Child-Specific Dietary Supplements
      • Herbal/Traditional Dietary Supplements
      • Herbal/Traditional Tonics and Bottled Nutritive Drinks
    • Allergy Care
      • Allergy Eye Care
      • Antihistamines/Allergy Remedies (Systemic)
      • Child-Specific Allergy Remedies
      • Topical Allergy Remedies/Antihistamines
    • Child-Specific Consumer Health
      • Child-Specific Analgesics
        • Child-Specific Acetaminophen
        • Child-Specific Aspirin
        • Child-Specific Combination Products - Analgesics
        • Child-Specific Diclofenac
        • Child-Specific Dipyrone
        • Child-Specific Ibuprofen
        • Child-Specific Ketoprofen
        • Child-Specific Naproxen
      • Child-Specific Cough, Cold and Allergy Remedies
        • Child-Specific Allergy Remedies
        • Child-Specific Cough/Cold Remedies
      • Child-Specific Digestive Remedies
        • Child-Specific Diarrhoeal Remedies
        • Child-Specific Indigestion and Heartburn Remedies
        • Child-Specific Laxatives
        • Child-Specific Motion Sickness Remedies
      • Child-Specific Medicated Skin Care
      • Nappy (Diaper) Rash Treatments
      • Child-Specific Vitamins and Dietary Supplements

Statistics Included

Statistics Included

For each category and subcategory you will receive the following data in Excel format:

From Passport

  • Market sizes
  • Company shares
  • Brand shares
  • Distribution
  • Analysis by format
  • Analysis by positioning
  • Analysis by type
  • Herbal/traditional vs standard
  • Pricing
  • Smoking population - number of adult smokers
  • Smoking prevalence - % of adult population

Market size details:

  • Retail volume
  • Retail volume % growth
  • Retail volume per capita
  • Retail value retail selling price % growth
  • Retail value retail selling price local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price real (constant 2008) prices % growth
  • Retail value retail selling price real (constant 2008) prices local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price real (constant 2008) prices per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price % growth
  • Retail value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price real (constant 2008) prices % growth
  • Retail value manufacturer selling price real (constant 2008) prices local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price real (constant 2008) prices per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price nominal (current) prices % growth
  • Retail value retail selling price nominal (current) prices local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price nominal (current) prices per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price nominal (current) prices % growth
  • Retail value manufacturer selling price nominal (current) prices local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price nominal (current) prices per capita local currency, USD, EUR, GBP, CHF, JPY

Methodology

Methodology

Global insight and local knowledge

With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

Industry specialists

Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

Country and regional analysts

Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

In-country research network

To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

Research Methodology

Our research methods

Each Euromonitor International industry report is based on a core set of research techniques:

Desk research

With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

  • National statistics offices governmental and official sources
  • National and international trade press
  • National and international trade associations
  • Industry study groups and other semi-official sources
  • Company financials and annual reports
  • Broker reports
  • Online databases
  • The financial, business and mainstream press

Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

Store checks

Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

  • Place: We track products in all relevant channels, selective and mass, store and non-store
  • Product: What are innovations in products, pack sizes and formats?
  • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
  • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

Trade survey

Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

Trade surveys allow us to:

  • Fill gaps in available published data per company
  • Generate a consensus view of the size, structure and strategic direction of the category
  • Access year-in-progress data where published sources are out of date
  • Evaluate the experts’ views on current trends and market developments

In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

Company analysis

At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

Forecasts

Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

Data validation

All data is subjected to an exhaustive review process, at country, regional and global levels.

The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

Market analysis

Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

my pages

Want to find out more about this report?

RELATED

Country Report

Consumer Lifestyle

Future Demographic

Country Report